ASCO Data Show A Battle Ahead For Roche And Genmab’s Lymphoma Bispecifics

Roche Leads But Rivals Could Have Efficacy Edge

Roche looks set to gain first and second place in the race to bring CD3xCD20s to market – but Genmab and AbbVie have a strong challenger.

ASCO 2019
The ASCO meeting returns to an in-person format in Chicago for the first time since 2019. • Source: ASCO

New data released ahead of the American Society of Clinical Oncology (ASCO) meeting confirms Roche’s strong position in a new class of B-cell non-Hodgkin’s lymphoma (NHL) therapies – but also makes clear that it faces tough competition from rivals Genmab and AbbVie.

Roche has not one, but two, CD3xCD20s bispecific antibody candidates in late-stage development for non-Hodgkin’s lymphoma, mosunetuzumab and glofitamab, both...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip